Arterial stiffness correlated with cardiac remodelling in patients with chronic kidney disease
MING-CHENG WANG, WEI-CHUAN TSAI,
JU-YI CHEN,
MENG-FU CHENG, JENG-JONG HUANG,
WEI-CHUAN TSAI
Cardiology, Department of Internal Medicine, National Cheng Kung University Hospital, Tainan, Taiwan
Search for more papers by this authorJU-YI CHEN
Cardiology, Department of Internal Medicine, National Cheng Kung University Hospital, Tainan, Taiwan
Search for more papers by this authorCorresponding Author
JENG-JONG HUANG
Divisions of Nephrology and
Dr Jeng-Jong Huang, Division of Nephrology, Department of Internal Medicine, National Cheng Kung University Hospital, 138 Sheng-Li Rd, Tainan, 70428, Taiwan. Email: [email protected]Search for more papers by this authorMING-CHENG WANG, WEI-CHUAN TSAI,
JU-YI CHEN,
MENG-FU CHENG, JENG-JONG HUANG,
WEI-CHUAN TSAI
Cardiology, Department of Internal Medicine, National Cheng Kung University Hospital, Tainan, Taiwan
Search for more papers by this authorJU-YI CHEN
Cardiology, Department of Internal Medicine, National Cheng Kung University Hospital, Tainan, Taiwan
Search for more papers by this authorCorresponding Author
JENG-JONG HUANG
Divisions of Nephrology and
Dr Jeng-Jong Huang, Division of Nephrology, Department of Internal Medicine, National Cheng Kung University Hospital, 138 Sheng-Li Rd, Tainan, 70428, Taiwan. Email: [email protected]Search for more papers by this authorSUMMARY:
Background: It is well known that both pressure and volume overloads contribute to left ventricular hypertrophy (LVH) and left ventricular dilatation in patients with chronic kidney disease (CKD). Few studies have evaluated the association between increased pulse wave velocity (PWV) and LVH in CKD patients not yet receiving dialysis. The purpose of this study was to assess the relationship between arterial stiffness and cardiac remodelling in patients with CKD, and to determine the independent factors associated with increased left ventricular mass index (LVMI) and left ventricular volume index (LVVI).
Methods: This cross-sectional study included 96 patients with CKD. Echocardiography and measurement of arterial stiffness by PWV were performed. Clinical and echocardiographic parameters were compared and analysed.
Results: Associated with the increase of PWV, there were significant trends for progressive increase in LVMI, LVH, LVVI, left ventricular dilatation and left atrium in CKD patients. Multivariate regression analysis revealed that decreased PWV, in addition to increased haemoglobin and the use of β-blocker, was an independent determinant associated with decrease in LVMI and LVVI.
Conclusion: Our study demonstrated the progressive structural remodelling of left ventricle and left atrium in CKD patients associated with increased severity of arterial stiffness. PWV was an important determinant of LVMI and LVVI in CKD patients.
REFERENCES
- 1 Jones CA, McQuillan GM, Kusek JW et al. Serum creatinine levels in the US population: Third National Health and Nutrition Examination Survey. Am. J. Kidney Dis. 1998; 32: 992–9.
- 2 National Kidney Foundation. K/DOQI clinical practice guidelines for chronic kidney disease: Evaluation, classification and stratification. Am. J. Kidney Dis. 2002; 39 (Suppl. 1): S37–45.
- 3 Shulman NB, Ford CE, Hall WD et al. Prognostic value of serum creatinine and effect of treatment of hypertension on renal function. Results from the hypertension detection and follow-up program. The Hypertension Detection and Follow-up Program Cooperative Group. Hypertension 1989; 13 (Suppl. 5): I80–93.
- 4 Sarnak MJ. Cardiovascular complications in chronic kidney disease. Am. J. Kidney Dis. 2003; 4 (Suppl. 5): S11–17.
- 5 Foley RN, Parfrey PS, Kent GM, Harnett JD, Murray DC, Barre PE. Long-term evolution of cardiomyopathy in dialysis patients. Kidney Int. 1998; 54: 1720–25.
- 6 Stewart GA, Gansevoort RT, Mark PB. Electrocardiographic abnormalities and uremic cardiomyopathy. Kidney Int. 2005; 67: 217–26.
- 7 Paoletti E, Bellino D, Cassottana P, Rolla D, Cannella G. Left ventricular hypertrophy in nondiabetic predialysis CKD. Am. J. Kidney Dis. 2005; 46: 320–27.
- 8 Foley RN, Parfrey PS, Harnett JD et al. Clinical and echocardiographic disease in patients starting end-stage renal disease therapy. Kidney Int. 1995; 47: 186–92.
- 9 Pfeffer MA, Braunwald E. Ventricular remodeling after myocardial infarction. Experimental observation and clinical implications. Circulation 1990; 81: 1161–72.
- 10 Gaudron P, Eilles C, Kugler I, Ertl G. Progressive left ventricular dysfunction and remodeling after myocardial infarction. Potential mechanisms and early predictors. Circulation 1993; 87: 755–63.
- 11 Vasan RS, Larson MG, Benjamin EJ, Evans J, Levy D. Left ventricular dilatation and the risk of congestive heart failure in people without myocardial infarction. N. Engl. J. Med. 1997; 336: 1350–55.
- 12 London GM, Fabiani F, Marchais SJ et al. Uremic cardiomyopathy: An inadequate left ventricular hypertrophy. Kidney Int. 1987; 31: 973–80.
- 13 Silberberg JS, Barre PE, Prichard SS, Sniderman AD. Impact of left ventricular hypertrophy on survival in end-stage renal disease. Kidney Int. 1989; 36: 289–90.
- 14 London GM, Marchais SJ, Safar ME et al. Aortic and large artery compliance in end-stage renal failure. Kidney Int. 1990; 37: 137–42.
- 15 London GM, Blacher J, Pannier B, Guerin AP, Marchais SJ, Safar ME. Arterial wave reflections and survival in end-stage renal failure. Hypertension 2001; 38: 434–8.
- 16 Marchais SJ, Guerin AP, Pannier BM, Levy BI, Safar ME, London GM. Wave reflections and cardiac hypertrophy in chronic uremia: Influence of body size. Hypertension 1993; 22: 876–83.
- 17 Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron 1976; 16: 31–41.
- 18 Wang MC, Tsai WC, Chen JY, Huang JJ. Stepwise increase in arterial stiffness corresponding with the stages of chronic kidney disease. Am. J. Kidney Dis. 2005; 45: 494–501.
- 19 Sahn DJ, DeMaria A, Kisslo J, Weyman A. Recommendations regarding quantification in M-mode echocardiography: Results of a survey of echocardiographic measurements. Circulation 1978; 58: 1072–83.
- 20 Devereux RB, Alonso DR, Lutas EM et al. Echocardiographic assessment of left ventricular hypertrophy: Comparison to necropsy findings. Am. J. Cardiol. 1986; 57: 450–58.
- 21 Casale PN, Devereux RB, Milner M et al. Value of echocardiographic measurement of left ventricular mass in predicting cardiovascular morbid events in hypertensive men. Ann. Intern. Med. 1986; 105: 173–8.
- 22 Phillips RA, Diamond JA. Ambulatory blood pressure monitoring and echocardiography – Noninvasive techniques for evaluation of the hypertensive patients. Prog. Cardiovasc. Dis. 1999; 41: 397–440.
- 23 Wang MC, Tseng CC, Tsai WC, Huang JJ. Blood pressure and left ventricular hypertrophy in patients on different peritoneal dialysis regimens. Perit. Dial. Int. 2001; 21: 36–42.
- 24 Pombo JF, Troy BL, Russell RO Jr. Left ventricular volumes and ejection fraction by echocardiography. Circulation 1971; 43: 480–90.
- 25 De Simone G. Left ventricular geometry and hypotension in end-stage renal disease: A mechanical perspective. J. Am. Soc. Nephrol. 2003; 142: 2421–7.
- 26 Middleton RJ, Parfrey PS, Foley RN. Left ventricular hypertrophy in the renal patient. J. Am. Soc. Nephrol. 2001; 12: 1079–84.
- 27 London GM. Pathophysiology of cardiovascular damage in the early renal population. Nephrol. Dial. Transplant. 2001; 16 (Suppl. 2): 3–6.
- 28 London GM. Left ventricular alterations and end-stage renal disease. Nephrol. Dial. Transplant. 2002; 17 (Suppl. 1): 29–36.
- 29 Levin A, Singer J, Thompson CR, Ross H, Lewis M. Prevalent left ventricular hypertrophy in the predialysis population: Identifying opportunities for intervention. Am. J. Kidney. Dis. 1996; 27: 347–54.
- 30 Tucker B, Fabbian F, Giles M, Thuraisingham RC, Raine AE, Baker LR. Left ventricular hypertrophy and ambulatory blood pressure monitoring in chronic renal failure. Nephrol. Dial. Transplant. 1997; 12: 724–8.
- 31 Levin A, Thompson CR, Ethier J et al. Left ventricular mass index increase in early renal disease: Impact of decline in hemoglobin. Am. J. Kidney Dis. 1999; 34: 125–34.
- 32 Murphy ST, Parfrey PS. The impact of anemia correction on cardiovascular disease in end-stage renal disease. Semin. Nephrol. 2000; 20: 350–55.
- 33 Eckardt KU. Managing a fateful alliance: Anaemia and cardiovascular outcomes. Nephrol. Dial. Transplant. 2005; 20 (Suppl. 6): vi16–20.
- 34 Hunt SA, Baker DW, Chin MH et al. American College of Cardiology/American Heart Association. ACC/AHA guidelines for the evaluation and management of chronic heart failure in the adult: Executive summary. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to revise the 1995 Guidelines for the Evaluation and Management of Heart Failure). J. Am. Coll. Cardiol. 2001; 38: 2101–13.
- 35 Hall SA, Cigarroa CG, Marcoux L, Risser RC, Grayburn PA, Eichhorn EJ. Time course of improvement in left ventricular function, mass and geometry in patients with congestive heart failure treated with beta-adrenergic blockade. J. Am. Coll. Cardiol. 1995; 25: 1154–61.
- 36 Prabhu SD, Chandrasekar B, Murray DR, Freeman GL. β-adrenergic blockade in developing heart failure: Effects on myocardial inflammatory cytokines, nitric oxide, and remodeling. Circulation 2000; 101: 2103–9.
- 37 Gheorghiade M, Colucci WS, Swedberg K. Beta-blockers in chronic heart failure. Circulation 2003; 107: 1570–75.
- 38 Muller-Brunotte R, Edner M, Malmqvist K, Kahan T. Irbesartan and atenolol improve diastolic function in patients with hypertensive left ventricular hypertrophy. J. Hypertens. 2005; 23: 633–40.
- 39 Suwelack B, Gerhardt U, Hausberg M, Rahn KH, Hohage H. Comparison of quinapril versus atenolol: Effects on blood pressure and cardiac mass after renal transplantation. Am. J. Cardiol. 2000; 86: 583–5, A10.
- 40 Dahlof B, Zanchetti A, Diez J et al. For the REGAAL Study Investigators. Effects of losartan and atenolol on left ventricular mass and neurohormonal profile in patients with essential hypertension and left ventricular hypertrophy. J. Hypertens. 2002; 20: 1855–64.
- 41 Liebson PR, Grandits GA, Dianzumba S et al. Comparison of five antihypertensive monotherapies and placebo for change in left ventricular mass in patients receiving nutritional-hygienic therapy in the treatment of mild hypertension study (TOMHS). Circulation 1995; 91: 698–706.
- 42 Gottdiener JS, Reda DJ, Massie BM, Materson BJ, Williams DW, Anderson RJ. Effect of single-drug therapy on reduction of left ventricular mass in mild to moderate hypertension. Circulation 1997; 95: 2007–14.
- 43 Agabiti-Rosei E, Trimarco B, Muiesan ML et al. ELSA Echocardiographic Substudy Group. Cardiac structural and functional changes during long-term antihypertensive treatment with lacidipine and atenolol in the European Lacidipine Study on Atherosclerosis (ELSA). J. Hypertens. 2005; 23: 1091–8.
Citing Literature
